Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IPH2102 at/kg · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| IPH2102 at 1 mg/kg | EXPERIMENTAL | lirilumab (IPH2102/BMS986015) at 1 mg/kg |
| IPH2102 at 0.1 mg/kg | EXPERIMENTAL | lirilumab (IPH2102/BMS986015) at 0.1 mg/kg |
| Placebo (Normal saline solution) | PLACEBO_COMPARATOR | Normal saline solution |
| Name | Type | Description |
|---|---|---|
| IPH2102 at 0.1 mg/kg | DRUG | every 3 months |
| IPH2102 at 1 mg/kg | DRUG | every 4 weeks |
| Placebo (normal saline solution) | DRUG | every 4 weeks |
Inclusion Criteria: 1. Primary or secondary Acute Myeloid Leukemia (AML, defined according to WHO 2008 criteria), in first CR/CRi (according to the revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Stand...
IPH2102 at/kg is an investigational small molecule being studied as a maintenance treatment for Acute Myeloid Leukemia (AML). It is being evaluated in a Phase 2 clinical trial to assess its efficacy in patients aged 60 years and older. The drug is not yet approved and remains in clinical development.
IPH2102 at/kg is a monoclonal antibody that targets KIR (killer cell immunoglobulin-like receptors) on natural killer cells. By blocking these receptors, it aims to enhance the immune system's ability to attack cancer cells. This mechanism is being investigated in the context of Acute Myeloid Leukemia maintenance therapy.
IPH2102 at/kg is being developed by Innate Pharma S.A., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Acute Myeloid Leukemia. Innate Pharma is listed on the stock exchange under the ticker IPHA.
IPH2102 at/kg is currently in Phase 2 clinical development. It is being studied as a maintenance treatment for Acute Myeloid Leukemia. The drug is investigational and has not been approved by regulatory authorities. A Phase 2 trial has been completed to evaluate its efficacy.
IPH2102 at/kg has one completed Phase 2 clinical trial with the identifier NCT01687387. The trial, titled 'Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)', enrolled 152 participants in France. The study was randomized, double-blind, and placebo-controlled, involving patients aged 60 years and older.
IPH2102 at/kg is an anti-KIR monoclonal antibody, as indicated by the clinical trial title. It is designed to target KIR receptors. The drug is being investigated for its potential role in maintenance treatment of Acute Myeloid Leukemia, though it remains in clinical development and is not yet approved.